Alkermes (ALKS) Financial Analysis & Valuation | Quarter Chart
Alkermes (ALKS)
ALKSPrice: $52.53
Fair Value: 🔒
🔒score
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable ... more
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical p... more
Description
Shares
| Market Cap | $8.76B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IE | CEO | Richard F. Pops |
| IPO Date | 1991-07-16 | CAGR | 0.17% |
| Employees | 2,095 | Website | www.alkermes.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.47% | Total Yield | 0.47% |
ALKS chart loading...
Fundamentals
Technicals
| Enterprise Value | $9.66B | P/E Ratio | 55.29 |
| Forward P/E | 33.75 | PEG Ratio | — |
| P/S Ratio | 7.9 | P/B Ratio | 7.03 |
| P/CF Ratio | 48.08 | P/FCF Ratio | 55.68 |
| EPS | $0.95 | EPS Growth 1Y | -56.94% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 3.21% | Gross Margin | 0.87% |
| Operating Margin | 0.12% | Profit Margin | 0.1% |
| ROE | 0.09% | ROA | 0.04% |
| ROCE | 0.05% | Current Ratio | 2.27 |
| Quick Ratio | 1.7 | Cash Ratio | 0.59 |
| Debt/Equity | 0.9 | Interest Coverage | 5.79 |
| Altman Z Score | 2.59 | Piotroski Score | 5 |